^(125)I粒子植入联合动脉灌注化疗治疗不可切除性肺癌  

Evaluation of ^(125)I seed implantation combined with arterial infusion chemotherapy in treating unresectable lung cancer

作　　者：刘瑞宝[1] 杨光[1] 崔亚利[1] 刘岩[1] 潘雪玲[1] 何东风[1] 马建群[1] 隋林[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院介入科,150081

出　　处：《介入放射学杂志》2009年第6期453-456,共4页Journal of Interventional Radiology

摘　　要：目的探讨CT引导下125I粒子植入联合动脉灌注化疗治疗不可切除肺癌的价值。方法30例不可切除性肺癌患者随机分为两组。A组14例,125I粒子植入术前或后1周内行动脉灌注化疗;B组16例,单纯125I粒子植入治疗。两组患者125I粒子植入2个月后行胸部CT检查,按RECIST标准判定疗效并进行生存分析。结果30例患者全部按计划完成治疗。A组植入粒子552枚,9例行了2次动脉灌注化疗;B组共植入125I粒子603枚。CT复查显示:A组完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)4例,进展(PD)0例,治疗有效率为71.4%;B组完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)5例,进展(PD)1例,治疗有效率为62.5%。两组治疗有效率差异无统计学意义(P>0.05)。1年生存率分别为78.6%和62.5%,生存期差异有统计学意义(P<0.05)。结论125I粒子植入联合动脉灌注化疗是治疗不可切除性肺癌的一种有效方法,可显著延长患者的生存期。Objective To assess the therapeutic effect of CT-guided 125^I seed implantation combined with arterial infusion chemotherapy in treating unresectable lung cancer. Methods Thirty patients with unresectable non-small call lung cancer were randomly divided into two groups. Group A （study group, n = 14）was receiving arterial infusion chemotherapy one week before and one week after 125^I seed implantation. Group B （control group, n = 16） was receiving 125^I seed implantation only. Two months after 125^Iseed implantation, follow-up checkup with thoracic CT scanning was carried out in all patients. The response to treatment was evaluated in accordance with RECIST criteria and the accumulated survival rate was analyzed by means of Kaplan-Meier. Results Scheduled treatment was completed in all 30 patients. Under CT- guidance, 552 125^I seeds were implanted in the patients of group A, while 603 125^I seeds were implanted in the patients of group B. Nine patients in group A received two times of arterial infusion chemotherapy. Follow- up CT examination showed that the case number of complete remission, partial remission, stabilized disease and progressive disease in group A was 0, 10, 4 and 0 respectively, with an overall response rate of 71.43%. The corresponding data in group B was 0, 10, 5 and 1 respectively, with an overall response rate of 62.5%. The difference in the response rate between two groups was of no statistical significance （P 〉 0.05 ）. The one- year survival rate of group A and B was 78.6% and 62.5% respectively, the difference between the two groups was statistically significant （P 〈 0.05）. Conclusion CT-guided 125^I seed implantation combined with arterial infusion chemotherapy is an effective treatment for unresectable lung cancer, it can significantly prolong the patient＇s survival time.

关 键 词：肺癌 125I粒子 组织间插植 动脉灌注化疗 介入 

分 类 号：R734.2[医药卫生—肿瘤]